The 2nd Health Innovation Euregion Event 2023 is intended for anyone who has the ambition to increase the innovation of products and services for human health. Either through entrepreneurship or through complementary partnerships. We do this by linking the ecosystems of Brightlands Maastricht Health Campus, Belgian and Dutch Limburg and North Rhine-Westphalia and showing what they can mean for entrepreneurs. Are you such a person? Then register now.
In practice, we often see that (starting) entrepreneurs and scientists have difficulty finding the right partners and organizations that can help them take the next steps in order to actually innovate. A shame!
How can we help this target group to further develop their valuable and promising inventions? By exchanging knowledge and experiences and learning from and with each other. To this end, we are organizing the 2nd Health Innovation Euregion Event 2023 in Maastricht on 27 June. We asked entrepreneurs, enterprising researchers, Medtronic, Rabobank and LIOF to candidly share their experiences and visions. Of course there is plenty of opportunity before and after to network and meet each other personally.
Participating in this event is free of charge!
6229 GV Maastricht
Program Health Innovation Euregion event 2023
|10.30h||Matchmaking||Make your own personal B2B Matchmaking agenda|
|12.00h||Lunch sponsored by Codex4SME|
|13.00h||Opening||Alderman Hubert Mackus, Municipality of Maastricht|
|13.15h||From EyeClinic (Maastricht UMC+) via InSciTe to Startup||Christian Bertens – Peyeoneer|
|13.30h||TBA||Enric Claverol-Tinturé – EIC|
|14.00h||From a Corporate to a Startup: Similarities, differences and lessons learned||Ann Belien – Rejuvenate Biotech|
|14.15h||Rabobank’s early stage ventures Financing instruments||Martijn Starre – Rabobank|
|15.15h||Essential founders financials||Jim Sargent – RQR Capital|
|15.45h||TBA||Victor Suturin – Aliform|
|16.00h||TBA||Dennie Tempel – SkylineDX|
|16.15h||Lessons learned from 10+ year Biotech CEO endeavour||Cristianne Rijcken – Cristal Therapeutics|
|16.45h||Failure of Charcot-Marie-tooth clinical trials due to lack of solid pre-clinical models||Esther Wolfs – BioMed instituut|
|17.00h||Conclusion & Closing|
|17.05h||Drinks & Networking|